AR074213A1 - Derivados de la espirociclobutilpiperidina - Google Patents

Derivados de la espirociclobutilpiperidina

Info

Publication number
AR074213A1
AR074213A1 ARP090104525A ARP090104525A AR074213A1 AR 074213 A1 AR074213 A1 AR 074213A1 AR P090104525 A ARP090104525 A AR P090104525A AR P090104525 A ARP090104525 A AR P090104525A AR 074213 A1 AR074213 A1 AR 074213A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
membered
aryl
membered heterocycloalkyl
Prior art date
Application number
ARP090104525A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR074213A1 publication Critical patent/AR074213A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmacéutica que comprende al menos un derivado de la espirociclobutilpiperidina divulgado en la presente y al menos un método para usar al menos un derivado de la espirociclobutilpiperidina divulgado en la presente para tratar al menos un trastorno asociado con el receptor H3 de la histamina como por ejemplo esquizofrenia, Alzheimer. Reivindicacion 1: Un compuesto de formula (1) o sales de formula (1) farmacéuticamente aceptables o mezclas de estos: en donde A es un resto del grupo en formulas (2); R1 es arilo, heteroarilo de 5 o 6 miembros, -S(=O)2R9, -C(=O)R10 o -C(=O)NR11R12; R2 es cicloalquilo C3-6 o alquilo C1-6; R3, R4, R5, R6, R7 y R8 se seleccionan cada uno, independientemente, entre hidrogeno y alquilo C1-3; R9, R10 y R11 se seleccionan cada uno, independientemente, entre alquilo C1-6, heterocicloalquilo de 4 miembros, heterocicloalquilo de 5 miembros, heterocicloalquilo de 6 miembros, heterocicloalquilo de 7 miembros, cicloalquilo C3-7, arilo, heteroarilo de 5 miembros, heteroarilo de 6 miembros, -alquil C1-3-heteroarilo de 5 miembros y -alquil C1-3-heteroarilo de 6 miembros, en donde dichos arilo y heteroarilo están sustituidos cada uno, independiente y opcionalmente por 1, 2 o 3 sustituyentes seleccionados entre halo, -CF3, ciano, alquilo C1-3, alcoxi C1-3 y -C(=O)NR13R14; R12 es H o alquilo C1-6; y R13 y R14 se seleccionan cada uno, independientemente, entre H y alquilo C1-3.
ARP090104525A 2008-11-25 2009-11-24 Derivados de la espirociclobutilpiperidina AR074213A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11776808P 2008-11-25 2008-11-25

Publications (1)

Publication Number Publication Date
AR074213A1 true AR074213A1 (es) 2010-12-29

Family

ID=42196890

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104525A AR074213A1 (es) 2008-11-25 2009-11-24 Derivados de la espirociclobutilpiperidina

Country Status (5)

Country Link
US (1) US20100130477A1 (es)
AR (1) AR074213A1 (es)
TW (1) TW201024276A (es)
UY (1) UY32258A (es)
WO (1) WO2010062245A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
WO2020077071A1 (en) * 2018-10-10 2020-04-16 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (fasn)
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2024032501A1 (zh) * 2022-08-08 2024-02-15 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2315494T3 (es) * 2002-04-26 2009-04-01 Schering Corporation Antagonistas muscarinicos.
BRPI0315644B8 (pt) * 2002-10-23 2021-05-25 Janssen Pharmaceutica Nv compostos de piperazinil e diazapanil benzamidas e benzotioamidas, suas composições e respectivos usos
DK1615909T3 (da) * 2003-04-23 2008-11-17 Glaxo Group Ltd Piperazin-derivater og deres anvendelse til behandling af neurologiske og psykiatriske sygdomme
PT1802307E (pt) * 2004-10-15 2008-06-06 Glaxo Group Ltd Derivados de pirrolidina como ligandos de receptores de histamina
EP1909797A4 (en) * 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
WO2008109336A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100113465A1 (en) * 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds

Also Published As

Publication number Publication date
TW201024276A (en) 2010-07-01
UY32258A (es) 2010-06-30
US20100130477A1 (en) 2010-05-27
WO2010062245A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
CO6321244A2 (es) Pirrolopiridinas como inhibidores de cinasa
ECSP11010912A (es) Compuestos de pirrol
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR080056A1 (es) Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2590504T3 (es) N-ciclilamidas como nematicidas
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR064355A1 (es) Herbicidas derivados de isoxazol
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR083169A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
PE20200447A1 (es) Compuestos de biheteroarilo y usos de los mismos
AR079260A1 (es) Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
HRP20140687T1 (hr) Derivati benzofurana
AR075510A1 (es) Inhibidores del virus de la hepatitis c
AR075531A1 (es) Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros
AR084913A1 (es) Derivados de aril-benzocicloalquil-amida
CO6241119A2 (es) Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1

Legal Events

Date Code Title Description
FB Suspension of granting procedure